Skip to main content
. 2005 Mar;7(3):193–199. doi: 10.1593/neo.04490

Figure 1.

Figure 1

Methylation analysis of a CpG island within the first exon of the PCDH-γ-A11 gene. (A) Bisulfite sequencing profile of a WHO grade II astrocytoma (7282) and normal brain (grey matter 12434). Methylated CpG sites 6 to 14 are indicated by arrows. Underlined are three BstUI restriction sites that are methylated and therefore conserved during bisulfite treatment in this tumor sample and are used for the restriction-based methylation assay. (B) Bisulfite sequencing analysis of CpG sites 1 to 26 of individual clones of the 312-bp PCDH-γ-A11 PCR product of four tumor samples (AII 7282, AII 11092, AII 12020, and GBM 4732) and two normal brain samples (white matter 12768, grey matter 12434). (▪) Methylated CpG site; (□) unmethylated CpG site. (C) Restriction-based methylation assay of the first exon of PCDH-γ-A11 in astrocytomas. The 312-bp bisulfite PCR products without (-) and after treatment (+) with BstUI restriction enzyme are shown. Restricted fragments of the PCR product are only apparent in tumor samples and not in the normal brain tissues (NB1, white matter 12284; NB2, white matter 12692; NB3, white matter 12768). Tumor samples AIII 2446, AIII 10414, and GBM 11637 also show no methylation in this assay.